Oct 06, 2018 Volume 392 Number 10154 p1167-1278 e10
Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial
Nicholas O Opoku, Didier K Bakajika, Eric M Kanza, Hayford Howard, Germain L Mambandu, Amos Nyathirombo, Maurice M Nigo, Kambale Kasonia, Safari L Masembe, Mupenzi Mumbere, Kambale Kataliko, Jemmah P Larbelee, Mawolo Kpawor, Kpehe M Bolay, Fatorma Bolay, Sampson Asare, Simon K Attah, George Olipoh, Michel Vaillant, Christine M Halleux, Ann
The morbidity and socioeconomic effects of onchocerciasis, a parasitic disease that is primarily endemic in sub-Saharan Africa, have motivated large morbidity and transmission control programmes. Annual community-directed ivermectin treatment has substantially reduced prevalence. Elimination requires intensified efforts, including more efficacious treatments. We compared parasitological efficacy and safety of moxidectin and ivermectin.